|
| Pathway name | LS_vs_control |
|
| Alpha6 beta4 integrin signaling pathway | 0.793 |
| Androgen receptor signaling pathway | 0.528 |
| Apoptosis mechanisms | 0.124 |
| B-cell receptor signaling pathway | 0.023 |
| G1 to S cell cycle control | 1 |
| Cell cycle | 0.487 |
| Delta-Notch signaling pathway | 0.226 |
| DNA replication | 1 |
| EGFR1 signaling pathway | 0.856 |
| FAS pathway and stress induction of HSP regulation | 1 |
| Focal Adhesion | 0.003 |
| G13 signaling pathway | 0.269 |
| G protein signaling pathways | 0.258 |
| Hedgehog signaling pathway | 1 |
| Apoptosis modulation by HSP70 | 1 |
| Id signaling pathway | 1 |
| IL-1 signaling pathway | 1 |
| IL-2 signaling pathway | 0.327 |
| IL-3 signaling pathway | 0.371 |
| IL-4 signaling pathway | 0.589 |
| IL-5 signaling pathway | 0.576 |
| IL-6 signaling pathway | 1 |
| IL-7 signaling pathway | 0.498 |
| IL-9 signaling pathway | 1 |
| Human insulin signaling | 0.387 |
| Integrin-mediated cell adhesion | 0.363 |
| Kit receptor signaling pathway | 0.051 |
| MAPK cascade | 1 |
| MAPK signaling pathway | 0.011 |
| mRNA processing (Homo sapiens) | 0.014 |
| Notch signaling pathway | 0.191 |
| Ovarian infertility genes | 1 |
| p38 MAPK signaling pathway (BioCarta) | 0.108 |
| Regulation of actin cytoskeleton | 0.834 |
| Eukaryotic transcription initiation | 0.511 |
| Signal transduction of S1P | 0.384 |
| Signaling of hepatocyte growth factor receptor | 1 |
| T cell receptor signaling pathway | 0.243 |
| TGF-beta receptor signaling pathway | 0.095 |
| TGF beta signaling pathway | 0 |
| TNF-alpha/NF-B signaling pathway | 0.752 |
| Translation factors | 0.368 |
| Wnt signaling pathway | 0.15 |
| Wnt signaling pathway | 0.051 |
| Acetylcholine synthesis | 1 |
| Alanine and aspartate metabolism | — |
| Biogenic amine synthesis | 1 |
| Cholesterol biosynthesis | 0.644 |
| Eicosanoid synthesis | 1 |
| Electron transport chain | 0.013 |
| Fatty acid beta oxidation 1 | 0.403 |
| Fatty acid beta oxidation 2 | 1 |
| Fatty acid beta oxidation 3 | 1 |
| Beta oxidation meta MAPP | 0.264 |
| Fatty acid omega oxidation | 0.687 |
| Fatty acid biosynthesis | 0.426 |
| Glucocorticoid and mineralcorticoid metabolism | 1 |
| Glutathione metabolism | 0.399 |
| Glycogen metabolism | 0.261 |
| Glycolysis and gluconeogenesis | 0.235 |
| Heme biosynthesis | 1 |
| TCA cycle | 0.24 |
| Mitochondrial LC-fatty acid beta-oxidation | 0.635 |
| Nuclear receptors in lipid metabolism and toxicity | 0.389 |
| Nucleotide metabolism | 0.622 |
| Pentose phosphate pathway | 1 |
| Prostaglandin synthesis and regulation | 1 |
| Statin pathway (PharmGKB) | 1 |
| Steroid biosynthesis | 1 |
| Synthesis and degradation of ketone bodies | 1 |
| Triacylglyceride synthesis | 0.419 |
| Tryptophan metabolism | 0.501 |
| Beta oxidation of unsaturated fatty acids | 1 |
| Urea cycle and metabolism of amino groups | — |
| GPCRs, class A rhodopsin-like | 0.317 |
| GPCRs, class B secretin-like | 1 |
| GPCRs, class C metabotropic glutamate, pheromone | 1 |
| GPCRs, other | 1 |
| Matrix metalloproteinases | 0.652 |
| Monoamine GPCRs | 1 |
| Nuclear receptors | 1 |
| Nucleotide GPCRs | 1 |
| Peptide GPCRs | 0.081 |
| Cytoplasmic ribosomal proteins | 0.025 |
| Small ligand GPCRs | 1 |
| ACE inhibitor pathway (Homo sapiens) | 0.254 |
| Adipogenesis human | 0.101 |
| Blood clotting cascade | 0.155 |
| Calcium regulation in the cardiac cell | 0.431 |
| Circadian exercise | 0.754 |
| Complement activation and classical pathway | 0.646 |
| Complement activation and classical pathway | 0.022 |
| Cytokines and inflammatory response (BioCarta) | 0 |
| Hypertrophy model | 0 |
| Inflammatory response pathway | 0.054 |
| Irinotecan pathway (Homo sapiens) | 0.685 |
| Oxidative stress | 0.402 |
| Proteasome degradation | 0.278 |
| Myometrial relaxation and contraction pathways | 0 |
| Striated muscle contraction | 0.427 |
|
